Prostate Cancer

>

Latest News

First-Line Olaparib/Abiraterone Shows Clinical Benefit in BRCA+ mCRPC
First-Line Olaparib/Abiraterone Shows Clinical Benefit in BRCA+ mCRPC

February 17th 2025

Olaparib plus abiraterone improved radiographic PFS and overall survival in mCRPC patients with germline or somatic BRCA mutations vs placebo plus abiraterone.

Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index
Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index

February 14th 2025

Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen
Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen

February 13th 2025

More adverse factors occurred in those with intermediate-risk prostate cancer undergoing neoadjuvant androgen deprivation therapy than those who did not.
EBRT Regimens Elicit 15-Year Prostate Cancer Survival Outcomes

February 13th 2025

Video Series
Video Interviews
Podcasts
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.
The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.
The recent episode of the "Oncology Peer Review On-The-Go" podcast features Alexandra Sokolova, MD, discussing her article on germline testing and NCCN guidelines for patients with prostate cancer.
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
On this week’s podcast, Jun Gong, MD, spoke with CancerNetwork® about the potential role of plasma glutamine as a biomarker for patients with localized prostate cancer.

More News